dc.contributor.author | Tiedje, Kathryn Ellen. | en_US |
dc.date.accessioned | 2014-10-21T12:33:35Z | |
dc.date.available | 2007 | |
dc.date.issued | 2007 | en_US |
dc.identifier.other | AAINR27202 | en_US |
dc.identifier.uri | http://hdl.handle.net/10222/54910 | |
dc.description | Epilepsy is a chronic neurological disorder whose main feature is the occurrence of recurrent seizures. In spite of the variability in epileptic symptoms, all have a common mechanistic basis, which results from excessive abnormal firing of a group of neurons known as the "seizure focus". Although new drug therapies are emerging, few offer any significant improvements over the drugs that have been conventionally used. | en_US |
dc.description | Drug therapies (anticonvulsants) that are presently available target the process of ictogenesis, "anti-ictogenic drugs" therefore act only to suppress the symptoms of epilepsy. Currently there are no drugs on the market that prevent the process of epileptogenesis, which is the development of a seizure focus after a traumatic brain injury. It is apparent that there is a great need for further research into new drug therapies that cannot only improve upon the anticonvulsants currently available, but also halt the pathological process of epileptogenesis. The primary goal of this research project is to discover a series of new pioneering "antiepileptogenic drugs" designed to prevent the onset of epilepsy after head injury, while also improving upon current "anti-ictogenic drugs". | en_US |
dc.description | The first research goal will be to design and synthesize novel anticonvulsant (antiseizure, anti-ictogenic) drugs based on nicotinamide. Surprisingly, nicotinamide derivatives have not been studied in medicinal chemistry, and their therapeutic potential remains unexploited. Nicotinamide derivatives will be developed as potential anti convulsants. | en_US |
dc.description | The second goal will be to design and synthesize novel anti-ictogenic/antiepileptogenic drugs based on a dihydrouracil structure. Through previous research that revealed the anti-epileptogenic properties of both R-alanine and uracil derivatives, it was concluded that research into the potential of dihydrouracils as putative drugs was an area that was in need of further development. Dihydrouracils derivatives will be developed as potential anti-ictogenic/antiepileptogenic "bioactive" prodrugs. | en_US |
dc.description | Thesis (Ph.D.)--Dalhousie University (Canada), 2007. | en_US |
dc.language | eng | en_US |
dc.publisher | Dalhousie University | en_US |
dc.publisher | | en_US |
dc.subject | Chemistry, Pharmaceutical. | en_US |
dc.title | The design and synthesis of anti-ictogenic and antiepileptogenic drugs based on endogenous molecules. | en_US |
dc.type | text | en_US |
dc.contributor.degree | Ph.D. | en_US |